These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

96 related articles for article (PubMed ID: 3545541)

  • 1. Distribution of cyclosporine in blood of a renal-transplant recipient with type V hyperlipoproteinemia.
    Verrill HL; Girgis RE; Easterling RE; Malhi BS; Mueller WF
    Clin Chem; 1987 Mar; 33(3):423-8. PubMed ID: 3545541
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of hematocrit on cyclosporine (cyclosporin A) in whole blood and plasma of renal-transplant patients.
    Rosano TG
    Clin Chem; 1985 Mar; 31(3):410-2. PubMed ID: 3882273
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Distribution of cyclosporin G (NVa2 cyclosporin) in blood and plasma.
    Yatscoff RW; Honcharik N; Lukowski M; Thliveris J; Chackowsky P; Faraci C
    Clin Chem; 1993 Feb; 39(2):213-7. PubMed ID: 8432008
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Liquid chromatography-tandem mass spectrometry method for simultaneous determination of cyclosporine A and its three metabolites AM1, AM9 and AM4N in whole blood and isolated lymphocytes in renal transplant patients.
    Brozmanová H; Perinová I; Halvová P; Grundmann M
    J Sep Sci; 2010 Aug; 33(15):2287-93. PubMed ID: 20589784
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Blood protein binding of cyclosporine in transplant patients.
    Zaghloul I; Ptachcinski RJ; Burckart GJ; Van Thiel D; Starzel TE; Venkataramanan R
    J Clin Pharmacol; 1987 Mar; 27(3):240-2. PubMed ID: 3316307
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Insights into the effects of hyperlipoproteinemia on cyclosporine A biodistribution and relationship to renal function.
    Aliabadi HM; Spencer TJ; Mahdipoor P; Lavasanifar A; Brocks DR
    AAPS J; 2006 Oct; 8(4):E672-81. PubMed ID: 17233531
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Relationships of cyclosporine concentrations in serum, whole blood, and bile after renal and hepatic transplantation.
    Vine W; Flye MW; Jatlow P
    Clin Chem; 1986 Oct; 32(10):1828-31. PubMed ID: 3530529
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cyclosporine kinetics in renal transplantation.
    Ptachcinski RJ; Venkataramanan R; Rosenthal JT; Burckart GJ; Taylor RJ; Hakala TR
    Clin Pharmacol Ther; 1985 Sep; 38(3):296-300. PubMed ID: 3896612
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A comparison of the clinical utility of the radioimmunoassay, high-performance liquid chromatography, and TDx cyclosporine assays in outpatient renal transplant recipients.
    Schroeder TJ; Brunson ME; Pesce AJ; Hindenlang LL; Mauser PA; Ruckrigl DI; Weibel ML; Wadih G; First MR
    Transplantation; 1989 Feb; 47(2):262-6. PubMed ID: 2645710
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Role of lipoproteins and erythrocytes in the in vitro binding and distribution of cyclosporin A in the blood.
    Lemaire M; Tillement JP
    J Pharm Pharmacol; 1982 Nov; 34(11):715-8. PubMed ID: 6129301
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [The significance and problem of cyclosporine blood level monitoring].
    Yuhki Y
    Rinsho Byori; 1990 Feb; 38(2):157-62. PubMed ID: 2184276
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The transport of cyclosporine in association with plasma lipoproteins in heart and liver transplant patients.
    Gurecki J; Warty V; Sanghvi A
    Transplant Proc; 1985 Aug; 17(4):1997-2002. PubMed ID: 3895642
    [No Abstract]   [Full Text] [Related]  

  • 13. Inhibition of lymphoproliferation by hyperlipoproteinemic plasma.
    Waddell CC; Taunton OD; Twomey JJ
    J Clin Invest; 1976 Oct; 58(4):950-4. PubMed ID: 184112
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A prospective study of cyclosporine concentration in relation to its therapeutic effect and toxicity after renal transplantation.
    Lindholm A; Dahlqvist R; Groth GG; Sjöqvist F
    Br J Clin Pharmacol; 1990 Sep; 30(3):443-52. PubMed ID: 2223423
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cyclosporine nephrotoxicity is minimized by adjusting dosage on the basis of drug concentration in blood.
    Moyer TP; Post GR; Sterioff S; Anderson CF
    Mayo Clin Proc; 1988 Mar; 63(3):241-7. PubMed ID: 3278174
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Determination of cyclosporine concentrations with monoclonal antibodies.
    Schran HF; Rosano TG; Hassell AE; Pell MA
    Clin Chem; 1987 Dec; 33(12):2225-9. PubMed ID: 3319290
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison and correlation of assays for monitoring cyclosporine drug levels in renal transplant recipients.
    Gibbons S; Grevel J; Reynolds K; Ried M; Rutzky LP; Kahan BD
    Transplant Proc; 1988 Apr; 20(2 Suppl 2):339-44. PubMed ID: 3284077
    [No Abstract]   [Full Text] [Related]  

  • 18. Cyclosporine monitoring in kidney and liver transplant patients: comparison between radioimmunoassay (37 degrees C plasma) and high-performance liquid chromatography (whole blood) measurements.
    Mojaverian P; Green PJ
    Transplant Proc; 1988 Apr; 20(2 Suppl 2):414-8. PubMed ID: 3284085
    [No Abstract]   [Full Text] [Related]  

  • 19. The pharmacokinetics of cyclosporine. II. Blood plasma distribution and binding studies.
    Awni WM; Sawchuk RJ
    Drug Metab Dispos; 1985; 13(2):133-8. PubMed ID: 2859158
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical pharmacokinetics of cyclosporin.
    Ptachcinski RJ; Venkataramanan R; Burckart GJ
    Clin Pharmacokinet; 1986; 11(2):107-32. PubMed ID: 3514043
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.